A record of results in enrollment, engagement and retention

We’ve conducted over 800 projects across Asia Pacific, EMEA, Latin America and North America. The proof of our ability is in our work, so we invite you to browse our case studies. They’re filled with examples of how we enrolled and engaged patients in studies that were just starting, falling behind, and/or in a race to market.

You can filter the case studies by therapeutic area and indication using the drop-downs below.

CLEAR FILTERING »

Cardiovasular

Hyperlipidemia/High Triglycerides

Acurian Delivers Thousands of Patients and Accelerates Enrollment Timelines for a Global Multi-Protocol Lipid Lowering Program

A sponsor’s injectable lipid lowering drug was in a first-to-market race against two competitors when it launched an eight-protocol, phase III global program. Six protocols were evaluating the LDL-C lowering efficacy, safety, and tolerability of the drug, and two studies were investigating its ability to reduce major cardiovascular events.

Endocrinology

Diabetic Foot Ulcers

Acurian Delivers 22% of Randomized Patients for a Phase II Trial of Patients with Diabetic Foot Ulcers

In order to begin phase III trials, a sponsor needed to complete the phase II study of its intramuscular injection therapy for patients who had diabetic foot ulcers with and without peripheral arterial disease. The plan was to randomize 133 dosed patients over an enrollment period of 26 months.

Cardiovasular

Hypertension

Acurian Delivers 895 Patients and Saves an Average of Two Months for a Five-protocol Hypertension Clinical Trial

A sponsor began a multi-protocol, one-year phase III study to evaluate the safety and tolerability of its drug in subjects with essential hypertension.

Respiratory

Pediatric Asthma

Acurian Shortens Enrollment Time by over Five Months for a Pediatric Asthma Study

A sponsor was in a tight race to market when it initiated a phase III, two-protocol clinical trial designed to evaluate the efficacy and safety of its inhaler-delivered drug in pediatric patients with persistent asthma.

Respiratory

Asthma

Acurian Delivers 32% of US Patient Randomizations to an Asthma Program

Respiratory disease is a core therapeutic area for this sponsor. When it announced the start of its Phase III program for its compound as a potential treatment for severe uncontrolled asthma, the sponsor was facing a crowded field. There were four other products in Phase III and multiple products in Phase II. Because this class of drug was in a race to approval, keeping the program on track and filing a BLA as quickly as possible were paramount.

Endocrinology

Type 1 Diabetes

Acurian Saves Four Months of Enrollment Time for a Type 1 Diabetes Study

A leading company in diabetes began phase III studies with the goal of expanding its portfolio with a next-generation basal insulin analog.

Gastroenterology

Crohn's Disease

With Acurian’s Help, a Crucial Crohn’s Disease Study Completes Enrollment 60% Faster

This mid-sized biopharmaceutical company’s growth strategy relies on the development of novel immunotherapy agents. One of its biologics carried the potential to treat a range of autoimmune diseases, including Crohn’s disease or CD.

Cardiovasular

Diabetes/Cardiovascular

Acurian Keeps Enrollment on Track and Saves Over $12 Million for a Sponsor of a Global Diabetes CV Outcomes Study

This seven-year outcomes study is critical to the success of a compound that is expected to build on the sponsor’s
leadership position in diabetes care.

Gastroenterology

GERD

Acurian Saves Over Three Months of Enrollment Time for a Phase IIb Gastroesophageal Reflux Disease (GERD) Study

The sponsor needed data from this study as quickly as possible in order to begin its phase III trial in patients with symptomatic GERD not completely responsive to proton pump inhibitors.

Women’s Health

Uterine Fibroids

Acurian shortens timelines by up to 20 months for a Uterine Fibroid program

This was an important phase III, two-protocol study for a first-in-class treatment of abdominal uterine bleeding in women with uterine fibroids.

The sponsor was facing significant enrollment challenges. Site start-up was delayed; sites were unable to meet their overly optimistic commitments to deliver enough patients; many patients were unwilling to wash off their current birth control medications to participate...

Endocrinology

Diabetes/Obesity / Type 2 Diabetes

Acurian Doubles Enrollment Rates of US Sites to Rescue a Global Diabetes Study

This was a critical phase III trial designed to be the most important study in this sponsor’s upcoming FDA submission for an innovative new Type 2 diabetes treatment.

Endocrinology

Diabetes/Obesity / Type 2 Diabetes

Acurian Helped to Put a Sponsor at the Forefront of a Chronic Disease Market

This sponsor was in a crucial race in the diabetes space as it began phase III clinical trials for a new class of drug for type 2 diabetes.

They were also rolling into a crowded field of companies developing competitive compounds. The competition was stiff, but the race was worth winning. If their drug was approved, it could capture a major share of a market that was projected to nearly double to $50 billion by 2022.